• Shahrokh Javaheri, Lee K Brown, William T Abraham, and Rami Khayat.
• Division of Pulmonary and Sleep Medicine, Bethesda North Hospital, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH. Electronic address: shahrokhjavaheri@icloud.com.
• Chest. 2020 Feb 1; 157 (2): 394-402.

AbstractSleep-disordered breathing (SDB), including OSA and central sleep apnea, is highly prevalent in patients with heart failure (HF). Multiple studies have reported this high prevalence in asymptomatic as well as symptomatic patients with reduced left ventricular ejection fraction (HFrEF), as well as in those with HF with preserved ejection fraction. The acute pathobiologic consequences of OSA, including exaggerated sympathetic activity, oxidative stress, and inflammation, eventually could lead to progressive left ventricular dysfunction, repeated hospitalization, and excessive mortality. Large numbers of observational studies and a few small randomized controlled trials have shown improvement in various cardiovascular consequences of SDB with treatment. There are no long-term randomized controlled trials to show improved survival of patients with HF and treatment of OSA. One trial of positive airway pressure treatment of OSA included patients with HF and showed no improvement in clinical outcomes. However, any conclusions derived from this trial must take into account several important pitfalls that have been extensively discussed in the literature. With the role of positive airway pressure as the sole therapy for SDB in HF increasingly questioned, a critical examination of long-accepted concepts in this field is needed. The objective of this review was to incorporate recent advances in the field into a phenotype-based approach to the management of OSA in HF.Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

29 keywords...

hide…